Metabolic syndrome is caused by an excessive energy intake in a long-term, high-fat and/or high-
sugar diet, resulting in
obesity and a series of related complications, which has become a global health concern. Probiotics intervention can regulate the gut microbiota and relieve the systemic and chronic low-grade
inflammation, which is an alternative to relieving
metabolic syndrome. The aim of this work was to explore the alleviation of two different Lactobacillusreuteri strains on
metabolic syndrome. Between the two L. reuteri strains, FYNLJ109L1 had a better improvement effect on
blood glucose, blood
lipid, liver tissue damage and other related indexes than NCIMB 30242. In particular, FYNLJ109L1 reduced
weight gain, food intake and fat accumulation. Additionally, it can regulate the gut microbiota, increase
IL-10, and reduce
IL-6 and
tumor necrosis factor-α (TNF-α), as well as liver injury, and further reduce
insulin resistance and regulate
lipid metabolism disorders. In addition, it could modulate the gut microbiota, particularly a decreased Romboutsia and Clostridium sensu stricto-1, and an increased Acetatifactor. The results indicated that FYNLJ109L1 could improve
metabolic syndrome significantly via alleviating
inflammation and gut microbiota modulation.